Pharmacotherapy in schizophrenia - Comparison of second generation antipsychotic agents

Harefuah

Volumn 144, Issue 4, 2005, Pages 285-290

  Melamed, Yuval ^a,d   Finkel, Boris ^a,d   Barak, Yoram ^b,d   Zipris, Patricia ^a,d   Oyffe, Igor ^a,d   Weizman, Abraham ^c,d   Bleich, Avi ^a,d  

^a LEV HASHARON MENTAL HEALTH CENTER   (Israel)

^b ABARBANEL MENTAL HEALTH CENTER   (Israel)

^c RABIN MEDICAL CENTER   (Israel)

^d TEL AVIV UNIVERSITY   (Israel)

Author keywords

Cost; Recommended guidelines; Second generations anti psychotic drugs; Side effects; Therapeutic algorithms

Indexed keywords

NEUROLEPTIC AGENT;

DRUG COMPARISON; REVIEW; SCHIZOPHRENIA; ALGORITHM; COMPARATIVE STUDY; HUMAN; PRACTICE GUIDELINE;

ALGORITHMS; ANTIPSYCHOTIC AGENTS; GUIDELINES; HUMANS; SCHIZOPHRENIA;

EID: 21244449074     PISSN: 00177768     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Kupfer DJ & Sartorius N, The usefulness and use of second-generation antipsychotic medication. Curr Opin Psychiatry, (Supplement) 2002; 15.
2. Expert consensus panel for optimizing pharmacologic treatment of psychotic disorders. Expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. J Clin Psychiatry, 2003; (64 Suppl) 12: 21-51.
3. Remington G & Kapur S, Atypical antipsychotics: are some more atypical than others? Psychopharmacology, 2000; 148: 3-15.
4. Conley RR & Mahmoud R, A randomized double-blind study of risperidone and clozapine in the treatment of schizophrenia or schizoaffective disorders. Am J Psychiatry, 2001; 158: 765-774.
5. Bhana N, Foster RH, Olney R & Plosker GL, Olanzapine. An updated review of its use in the management of schizophrenia. Drugs, 2001; 61: 1-50.
6. Kasper S & Muller-Spahn F, Review of Quetiapine and its clinical applications in schizophrenia. Exp Opin Pharmacother, 2000; 1: 783-801.
7. Weiden PJ, Iqbal N, Mendelowitz AJ & al, Best clinical practice with Ziprasidone: update after one year of experience. J Psychiatric Practice, 2002; 8: 81-98.
8. Mota Neto JIS, Lima MS & Soares BGO, Amisulpride for schizophrenia. The Cochrane Library, 2, 2004.
9. Taylor DM & McAskill R, Atypical antipsychotics and weight gain - a systematic review. Acta Psychiatry Scand, 2000; 101: 416-432.
10. Meaney AM & O'Keane V, Prolactin and schizophrenia: clinical consequences of hyperprolacinaemia. Life Sciences, 2002; 71: 979-992.
11. Cutler AJ, Sexual dysfunction and antipsychotic treatment. Psychoneuroendocrinology, 2003; 28: 69-82.
12. Wang PS, Walker AM, Tsuang MT & al, Dopamine antagonists and the development of breast cancer. Arch Gen Psychiatry, 2002; 59: 1147-1154.
13. Allison DB, Mentore JL, Heo M & al, Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry, 1999; 156: 1686-1696.
14. American Diabetes Association, American Psychiatric Association, American Association of clinical Endocrinologists, North American Associaton for the study of obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry, 2004; 65: 267-272.
15. Wirshing DA, Wirshing WC, Kysar L & al, Novel antipsychotics: comparison of weight gain liabilities. J Clin Psychiatry, 1999; 60: 358-363.
16. Baptista T, Obesity and related metabolic abnormalities during antipsychotic drug administration: Mechanisms, management and research perspectives. Pharacopsychiatry, 2002; 205-219.
17. Wilson DR, D'soura L, Sarkar N & al, New-onset diabetes and ketoacidosis with atypical antipsychotics. Schizophr Res, 2003; 59: 1-6.
18. Sernyak MJ, Leslie DL, Alarcon RD & al, Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry, 2002; 159: 561-566.
19. Koro CE, Fedder DO, L' Italien GJ & al, Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. BMJ, 2002; 325: 1-5.
20. Newcomer JW, Haupt DW, Fucetola R & al, Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry, 2002; 59: 337-345.
21. Lindenmayer JP, Czobor P, Volavka J & al, Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry, 2003; 160: 290-296.
22. Meyer JM, A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year. J Clin Psychiatry, 2002; 63: 425-433.
23. Gregory C & Mckenna P, Pharmacological management of schizophrenia in older patients. Drugs Aging, 1994; 5: 254-262.
24. Barak Y, No weight gain among elderly schizophrenic patients after 1 year of risperidone treatment. J Clin psychiatry, 2002; 63: 117-119.
25. Barak Y & Aizenberg D, Effects of olanzapine on lipid abnormalities in elderly psychotic patients. Drug Aging, 2003; 20: 893-896.
26. Herrmann N, Mamdani M & Lanctot KL, Atypical antipsychotics and risk of cerebrovascular accidents. Am J Psychiatry, 2004; 161: 1113-1115.
27. Gilbody SM, Bagnall AM, Duggan L & Tuunainen A, Risperidone versus other atypical antipsychotic medication for schizophrenia. The Cochrane Library, 2004, 2.
28. Wahlbeck K, Cheine M, Tuisku K & al, Risperdone versus clozapine in treatment-resistant schizophrenia: a randomized pilot study. Prog Neuro-Pharmacol & Biol Psychiatry, 2000; 24: 911-922.
29. Dossenbach MRK, Beuzen JN, Avnon M & al, The effectiveness of olanzapine in treatment-refractory schizophrenia when patients are nonresponsive to or unable to tolerate clozapine. Clin Ther, 2000; 22: 1021-1034.
30. Sprague DA, Selection of atypical antipsychotics for the management of schizophrenia. Annals Pharmacotherapy, 2003; 38: 313-319.
31. Rosenheck R, Perlick D, Bingham S & al, Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia. J Am Med Assoc, 2003; 290: 2693-2702.
32. Barak Y, Mirecki I, Knobler H & al, Suicidality and second generation artipsycotics in schizophrenia patients, a case-controlled retrospective study during a 5 year period. Psychoparmacology, 2004. In press.
33. Meyer PS, Bond GR, Tunis SL & McCoy ML, Comparison between the effects of atypical and traditional antipsychotics on work status for clients in a psychiatric rehabilitation program. J Clin Psychiatry, 2002; 63: 108-116.
34. Rush AJ, Rago WV, Crismon ML & al, Medication treatment for the severely and persistently mentally ill: The Texas Medication Algorithm Project. J Clin Psychiatry, 1999; 60: 284-291.
35. Canadian Clinical Practice Guidelines for the Treatment of Schizophrenic. The Can J Psychiatry, 1998; 43(Suppl 2): 25-40.
36. Miller AL, Chiles JA, Chiles JK & al, The Texas Medication Algorithm Project (TMAP) schizophrenia algorithms. J Clin Psychiatry, 1999; 60: 649-657.
37. Finnerty M, Recommendations for the pharmacological management of schizophrenia. New York State Office of Mental Health.
38. Department of Veterans Affairs, Pharmacy benefits management. Medical advisory panel and mental health, strategic healthcare group. Guideline for atypical use. 2002.
39. Expert Consensus Guideline. Using antipsychotic agents in old patients. J Clin Psychiatry, 2004; 65 (Suppl 2): 1-131.
40. Belmaker EH & Bersudsky Y, Editorial: a rational approach to the use of atypical antipsychotics. Isr J Psychiatry, 2003; 40: 79-81.